1. Home
  2. PX vs TRVI Comparison

PX vs TRVI Comparison

Compare PX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PX
  • TRVI
  • Stock Information
  • Founded
  • PX 1992
  • TRVI 2011
  • Country
  • PX United States
  • TRVI United States
  • Employees
  • PX N/A
  • TRVI N/A
  • Industry
  • PX Investment Managers
  • TRVI Biotechnology: Pharmaceutical Preparations
  • Sector
  • PX Finance
  • TRVI Health Care
  • Exchange
  • PX Nasdaq
  • TRVI Nasdaq
  • Market Cap
  • PX 1.4B
  • TRVI 1.4B
  • IPO Year
  • PX 2021
  • TRVI 2019
  • Fundamental
  • Price
  • PX $10.54
  • TRVI $11.10
  • Analyst Decision
  • PX Buy
  • TRVI Strong Buy
  • Analyst Count
  • PX 6
  • TRVI 9
  • Target Price
  • PX $15.25
  • TRVI $20.72
  • AVG Volume (30 Days)
  • PX 386.9K
  • TRVI 1.6M
  • Earning Date
  • PX 11-06-2025
  • TRVI 11-13-2025
  • Dividend Yield
  • PX 1.42%
  • TRVI N/A
  • EPS Growth
  • PX 38.11
  • TRVI N/A
  • EPS
  • PX 0.14
  • TRVI N/A
  • Revenue
  • PX $301,314,000.00
  • TRVI N/A
  • Revenue This Year
  • PX $4.31
  • TRVI N/A
  • Revenue Next Year
  • PX $18.45
  • TRVI N/A
  • P/E Ratio
  • PX $75.72
  • TRVI N/A
  • Revenue Growth
  • PX 9.77
  • TRVI N/A
  • 52 Week Low
  • PX $8.85
  • TRVI $2.36
  • 52 Week High
  • PX $14.28
  • TRVI $11.83
  • Technical
  • Relative Strength Index (RSI)
  • PX 46.27
  • TRVI 60.59
  • Support Level
  • PX $10.07
  • TRVI $10.22
  • Resistance Level
  • PX $10.98
  • TRVI $11.82
  • Average True Range (ATR)
  • PX 0.33
  • TRVI 0.57
  • MACD
  • PX 0.04
  • TRVI -0.05
  • Stochastic Oscillator
  • PX 53.16
  • TRVI 55.00

About PX P10 Inc.

P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Share on Social Networks: